Multidisciplinary Perspectives on the Evolving Management of EGFR-Mutated Metastatic NSCLC

This content was funded by AstraZeneca.

As the treatment landscape for epidermal growth factor receptor-mutated metastatic non-small cell lung cancer grows, clinical decision-making becomes increasingly complex. In this expert discussion, medical oncologist Jacob Sands, advanced practice provider Beth Sandy, and pharmacist Stefanie Houseknecht explore how treatment selection, sequencing, toxicity, and patient preferences can support personalized care.

Listen as the experts navigate:

• Individualizing treatment decisions: how treatment choice is influenced by options across lines of therapy, patient preferences, and practical considerations  
• The value of multidisciplinary collaboration: how oncologists, nurse practitioners, pharmacists, and infusion teams contribute different perspectives to the treatment pathway 
• Supporting patients throughout the treatment journey: the importance of clear education, expectation setting, and open communication

This discussion reflects the speakers’ clinical experience and opinions. The occurrence and severity of adverse events differ between patients and cannot be predicted for any individual.

1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
2. Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA
3. Johns Hopkins Bayview Medical Center, Baltimore, Maryland, USA

US-116872 Last Updated 9/26